Mustafa Dohadwala, MD
Clinical Cardiac Electrophysiology · Dallas, TXNPI 1275732604
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Abbott at 48.2% of the total. 2025 is the largest year on record at $54,214, more than ten times the $4,240 reported in 2019.
Across 434 payments — averaging $278.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$58K
- Boston Scientific$34K
- Philips North America LLC$14K
- Medtronic$7K
- Medical Device Business Services, Inc.$3K
- Impulse Dynamics (USA) Inc.$2K
- plus $3K from 25 others
Across 33 payments — averaging $20,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$693K
What the payments were for
- Consulting fees$60,33850%
- Speaking & faculty fees$28,98824%
- Travel & lodging$18,73315%
- Food & beverage$12,95711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 87 | $58,284 |
| Boston Scientific | 137 | $33,876 |
| Philips North America LLC | 22 | $13,914 |
| Medtronic(2 entities) | 29 | $7,197 |
| Medical Device Business Services, Inc. | 8 | $2,775 |
| Impulse Dynamics (USA) Inc. | 33 | $2,322 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $592 |
| Sanofi-aventis U.S. LLC | 21 | $368 |
| Johnson & Johnson | 16 | $315 |
| Biosense Webster, Inc. | 8 | $288 |
| Pfizer | 10 | $237 |
| E.r. Squibb & Sons, L.L.C. | 6 | $127 |
| Irhythm Technologies, Inc. | 5 | $106 |
| Cardiva Medical, Inc. | 3 | $99 |
| Atricure, Inc. | 2 | $83 |
| Elutia, Inc. | 5 | $75 |
| Altathera Pharmaceuticals LLC | 2 | $43 |
| Inari Medical, Inc. | 1 | $39 |
| Baxter Healthcare | 2 | $34 |
| Angiodynamics, Inc. | 1 | $31 |
| Stereotaxis Inc | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Cordis US CORP. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| ZOLL Respicardia, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Amgen | 1 | $15 |
| B. Braun Interventional Systems Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$56,608
- WATCHMAN Access System$12,625
- (9520) IGT Devices Undivided$11,622
- GENERAL - THERAPIES$6,966
- OPTIMIZER$3,262
- Carto 3 System$2,775
- CLINICAL TRIAL PRODUCT$1,250
- (9124) LM Undivided$1,096
- Watchman$729
- IGT Devices Und$603
- ENSITE$284
- Farapulse$167
- COBALT DR MRI SURESCAN$164
- Micra$157
- Carto 3$146
- SelectSecure$113
- Lasers$110
How this compares
$121,015 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 304 | $354,591 |
| XareltoRivaroxaban | 99 | $123,142 |
| MultaqDronedarone Hcl | 30 | $44,409 |
| Metoprolol Succinate | 269 | $3,723 |
| Propafenone Hcl ErPropafenone Hcl | 13 | $3,068 |
| Flecainide Acetate | 61 | $2,466 |
| ClopidogrelClopidogrel Bisulfate | 105 | $1,279 |
| SotalolSotalol Hcl | 34 | $721 |
| Sucralfate | 17 | $364 |
| Carvedilol | 46 | $257 |
| Metoprolol Tartrate | 64 | $256 |
| Amiodarone Hcl | 11 | $220 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $176 |
| Losartan Potassium | 19 | $128 |
| Pantoprazole Sodium | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $237 | $354,591304 claims |
| Johnson & JohnsonXarelto | $315 | $123,14299 claims |
| Sanofi-aventis U.S. LLCMultaq | $368 | $44,40930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Dallas
- Russell CanhamDallas$184K
- Usama DaimeeDallas$102K
- Brian leDallas$102K
- Mohammad ShaarDallas$87K
- Praveen RaoDallas$67K
- Michael DelaughterBedford$1.6M
- Andrea NataleAustin$1.3M
- Jason ZagrodzkyAustin$961K
- Amin Al-AhmadAustin$771K
- Dale YooMcKinney$585K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.